These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15115750)

  • 41. Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids.
    Ho JJ; Cheng S; Kim YS
    Biochem Biophys Res Commun; 1995 May; 210(3):866-73. PubMed ID: 7539263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
    Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
    J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specificity clusters of MUC1-reactive mouse monoclonal antibodies.
    Hanisch FG
    Tumour Biol; 1998; 19 Suppl 1():111-7. PubMed ID: 9422095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
    Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC
    Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
    Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
    Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
    Matsushita T; Takada W; Igarashi K; Naruchi K; Miyoshi R; Garcia-Martin F; Amano M; Hinou H; Nishimura S
    Biochim Biophys Acta; 2014 Mar; 1840(3):1105-16. PubMed ID: 24246952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls.
    Imbert Y; Darling DS; Jumblatt MM; Foulks GN; Couzin EG; Steele PS; Young WW
    Exp Eye Res; 2006 Sep; 83(3):493-501. PubMed ID: 16631167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase.
    Olson FJ; Bäckström M; Karlsson H; Burchell J; Hansson GC
    Glycobiology; 2005 Feb; 15(2):177-91. PubMed ID: 15456735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein.
    Kirnarsky L; Prakash O; Vogen SM; Nomoto M; Hollingsworth MA; Sherman S
    Biochemistry; 2000 Oct; 39(39):12076-82. PubMed ID: 11009623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity.
    Westerlind U; Schröder H; Hobel A; Gaidzik N; Kaiser A; Niemeyer CM; Schmitt E; Waldmann H; Kunz H
    Angew Chem Int Ed Engl; 2009; 48(44):8263-7. PubMed ID: 19718733
    [No Abstract]   [Full Text] [Related]  

  • 51. Antigens for the selection of pan-variable number of tandem repeats motif-specific human antibodies against Mucin-1.
    Persson J; Ohlin M
    J Immunol Methods; 2006 Oct; 316(1-2):116-24. PubMed ID: 17022996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles.
    Engelmann K; Kinlough CL; Müller S; Razawi H; Baldus SE; Hughey RP; Hanisch FG
    Glycobiology; 2005 Nov; 15(11):1111-24. PubMed ID: 15972891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Binding patterns of 51 monoclonal antibodies to peptide and carbohydrate epitopes of the epithelial mucin (MUC1) on tissue sections of adenolymphomas of the parotid (Warthin's tumours): role of epitope masking by glycans.
    Cao Y; Karsten U
    Histochem Cell Biol; 2001 Apr; 115(4):349-56. PubMed ID: 11405064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
    Spencer DI; Price MR; Tendler SJ; De Matteis CI; Stadie T; Hanisch FG
    Cancer Lett; 1996 Feb; 100(1-2):11-5. PubMed ID: 8620429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
    Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
    Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
    von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
    Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthetic glycopeptides for the development of tumour-selective vaccines.
    Kunz H
    J Pept Sci; 2003 Sep; 9(9):563-73. PubMed ID: 14552419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues.
    Wagner S; Mersch C; Hoffmann-Röder A
    Chemistry; 2010 Jun; 16(24):7319-30. PubMed ID: 20461825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.
    van Leeuwen EB; Cloosen S; Senden-Gijsbers BL; Agervig Tarp M; Mandel U; Clausen H; Havenga MJ; Duffour MT; García-Vallejo JJ; Germeraad WT; Bos GM
    Cytotherapy; 2006; 8(1):24-35. PubMed ID: 16627342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
    Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
    Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.